Immunotherapeutic agents in relapsed/refractory indolent B-NHL
| Study . | Drug . | Disease . | n . | ORR . | CR . | DOR . | PFS . |
|---|---|---|---|---|---|---|---|
| CheckMate 140 | Nivolumab | FL | 92 | 4% | 1% | 10.4 mo | 2.2 mo |
| Nastoupil et al 37 | R-pembrolizumab | FL | 30 | 64% | 48% | NR at 11 mo | NA |
| Gopal et al38 | R-utomilumab | FL | 33 | 27% | 17% | NA | NA |
| Advani et al 39 | Hu5F9 | FL | 7 | 71% | 43% | 91% at 8.1 mo | NA |
| Morschhauser et al40 | R-polatuzumab | FL | 20 | 70% | 45% | NA | NA |
| Sehn et al42 | BR-polatuzumab | FL | 39 | NA | 69% | NA | 17 mo |
| Caimi et al43 | Loncastuximab tesirine | FL | 15 | 80% | 53.3% | NR at 7.56 mo | NR at 7.56 mo |
| Jurczak et al44 | MOR208 | FL | 34 | 29% | 9% | 12 mo | 8.8m |
| Goebeler et al45 | Blinatumomab | FL | 28 | 80% | 40% | NA | NA |
| Schuster et al49 | 19-41BBz CAR T cells | FL | 14 | 79% | 71% | 89% at 28.6 mo | 70% at 28.6 mo |
| Study . | Drug . | Disease . | n . | ORR . | CR . | DOR . | PFS . |
|---|---|---|---|---|---|---|---|
| CheckMate 140 | Nivolumab | FL | 92 | 4% | 1% | 10.4 mo | 2.2 mo |
| Nastoupil et al 37 | R-pembrolizumab | FL | 30 | 64% | 48% | NR at 11 mo | NA |
| Gopal et al38 | R-utomilumab | FL | 33 | 27% | 17% | NA | NA |
| Advani et al 39 | Hu5F9 | FL | 7 | 71% | 43% | 91% at 8.1 mo | NA |
| Morschhauser et al40 | R-polatuzumab | FL | 20 | 70% | 45% | NA | NA |
| Sehn et al42 | BR-polatuzumab | FL | 39 | NA | 69% | NA | 17 mo |
| Caimi et al43 | Loncastuximab tesirine | FL | 15 | 80% | 53.3% | NR at 7.56 mo | NR at 7.56 mo |
| Jurczak et al44 | MOR208 | FL | 34 | 29% | 9% | 12 mo | 8.8m |
| Goebeler et al45 | Blinatumomab | FL | 28 | 80% | 40% | NA | NA |
| Schuster et al49 | 19-41BBz CAR T cells | FL | 14 | 79% | 71% | 89% at 28.6 mo | 70% at 28.6 mo |
B-NHL, B-cell non-Hodgkin lymphoma; BR, bendamustine rituximab; CAR, chimeric antigen receptor; CR, complete response; DOR, duration of response; FL, follicular lymphoma; NA, not reported; ORR, overall response rate; PFS, progression-free survival; R, rituximab.